Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

NRBO

NeuroBo Pharmaceuticals Inc

Apr 19 • 04:00PM ET

3.37

Dollar change -0.07
Percentage change -2.03	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF DFAS DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.46	Insider Own	59.79%	Shs Outstand	4.91M	Perf Week	-6.65%
Market Cap	16.55M	Forward P/E	-	EPS next Y	-1.90	Insider Trans	0.00%	Shs Float	1.97M	Perf Month	-23.23%
Income	-12.47M	PEG	-	EPS next Q	-1.25	Inst Own	2.09%	Short Float	3.14%	Perf Quarter	1.20%
Sales	0.00M	P/S	-	EPS this Y	-21.95%	Inst Trans	-29.02%	Short Ratio	0.05	Perf Half Y	-3.16%
Book/sh	3.40	P/B	0.99	EPS next Y	36.83%	ROA	-44.29%	Short Interest	0.06M	Perf Year	-39.82%
Cash/sh	4.57	P/C	0.74	EPS next 5Y	-	ROE	-64.89%	52W Range	2.89 - 6.75	Perf YTD	-8.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	69.13%	ROI	-74.13%	52W High	-50.07%	Beta	-0.25
Dividend TTM	-	Quick Ratio	3.78	Sales past 5Y	0.00%	Gross Margin	-	52W Low	16.66%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	3.78	EPS Y/Y TTM	97.11%	Oper. Margin	0.00%	RSI (14)	31.82	Volatility	7.24% 7.31%
Employees	8	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	36.50
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	28.87%	Payout	-	Rel Volume	0.02	Prev Close	3.44
Sales Surprise	-	EPS Surprise	-33.76%	Sales Q/Q	-	Earnings	Mar 28 BMO	Avg Volume	1.33M	Price	3.37
SMA20	-13.46%	SMA50	-27.26%	SMA200	-15.97%	Trades		Volume	20,537	Change	-2.03%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-15-20	Initiated	H.C. Wainwright	Buy	$20

Apr-17-24 08:05AM	NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity (PR Newswire)
Apr-01-24 08:01AM	NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire)
Mar-28-24 08:01AM	NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update (PR Newswire) -5.76%
Mar-13-24 08:01AM	NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire) -8.21%
Mar-04-24 08:01AM	NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer (PR Newswire)
08:01AM	Loading…
Feb-29-24 08:01AM	NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity (PR Newswire) +13.09%
Feb-12-24 08:01AM	NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference (PR Newswire) +9.65%
Feb-01-24 08:01AM	NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity (PR Newswire) +67.28%
Jan-18-24 08:01AM	NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire)
Jan-09-24 08:30AM	NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement (PR Newswire)
Jan-02-24 08:01AM	NeuroBo to Participate in Industry and Investor Conferences in January (PR Newswire) +11.24%
Dec-28-23 08:45AM	NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity (PR Newswire) +21.23%
Dec-19-23 08:43AM	NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split (PR Newswire) -23.55%
Dec-15-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Dec-12-23 01:02PM	Life Science Investor Forum Agenda Announced for December 14th, 2023 (GlobeNewswire)
08:31AM	Loading…
Dec-01-23 08:31AM	NeuroBo to Participate in Investor Conferences in December (PR Newswire)
Nov-13-23 04:05PM	NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-06-23 08:05AM	NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D. (PR Newswire)
Oct-17-23 08:01AM	NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference (PR Newswire)
Sep-15-23 08:01AM	NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH (PR Newswire) +18.80%
Aug-14-23 08:01AM	NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT (PR Newswire)
Aug-09-23 04:05PM	NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Aug-03-23 08:01AM	NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH (PR Newswire) -6.16%
Aug-02-23 08:01AM	NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01 (PR Newswire) +10.89%
Jun-27-23 08:01AM	NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models (PR Newswire) +23.05%
Jun-13-23 08:01AM	NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions (PR Newswire)
May-12-23 08:00AM	NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors (PR Newswire)
May-02-23 08:01AM	NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH (PR Newswire) -9.08%
Apr-03-23 08:00AM	NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH (PR Newswire)
Mar-30-23 04:40PM	NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results (PR Newswire)
08:00AM	Loading…
Jan-18-23 08:00AM	NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President (PR Newswire)
Nov-08-22 04:05PM	NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT (PR Newswire) -42.13%
Nov-04-22 09:15AM	NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT (PR Newswire) -44.11%
Sep-29-22 08:30AM	NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria (PR Newswire) -6.15%
Sep-15-22 08:30AM	NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies (PR Newswire) +47.21%
Sep-12-22 09:15AM	NeuroBo Pharmaceuticals Announces Reverse Stock Split (PR Newswire) +101.30%
May-06-22 08:00AM	NeuroBo Pharmaceuticals, Inc. Expands Management Team with the Appointment of Matthew Bardin, PharmD, BCPS as Senior Vice President Operations (PR Newswire)
Apr-01-22 08:00AM	NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results (PR Newswire)
Mar-15-22 08:00AM	NeuroBo Pharmaceuticals, Inc. Expands Scientific Advisory Board with Appointment of Danamarie Belpulsi, M.D. (PR Newswire) +6.54%
Jan-28-22 04:30PM	NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors (PR Newswire)
Nov-15-21 08:00AM	NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-04-21 08:00AM	NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer (PR Newswire)
Oct-13-21 08:00AM	NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19 (PR Newswire) +6.52%
Oct-05-21 01:13PM	NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering (PR Newswire) -7.17%
Oct-01-21 08:00AM	NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering (PR Newswire) -32.80%
Sep-03-21 11:27AM	Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like (Simply Wall St.) -7.52%
Aug-16-21 08:00AM	NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results (PR Newswire)
Jul-12-21 08:30AM	NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors (PR Newswire)
May-17-21 05:02PM	NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results (PR Newswire) +5.56%
Apr-15-21 04:52PM	NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update (PR Newswire)
Mar-24-21 08:00AM	NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene (PR Newswire)
Mar-05-21 08:30AM	NeuroBo Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference (PR Newswire)
Jan-21-21 04:05PM	NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement (PR Newswire)
Jan-19-21 08:00AM	NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement (PR Newswire) -13.93%
Jan-06-21 08:30AM	NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program (PR Newswire) +19.93%
Dec-21-20 05:08AM	Is NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Popular Amongst Insiders? (Simply Wall St.)
Nov-13-20 04:30PM	NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results (PR Newswire)
Sep-02-20 08:30AM	NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors (PR Newswire)
Aug-11-20 03:00PM	NeuroBo Pharmaceuticals Reports Second Quarter 2020 Financial Results (PR Newswire) -8.40%
Jun-16-20 04:05PM	NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes (PR Newswire)
May-26-20 08:30AM	NeuroBo Pharmaceuticals Announces Continuation of Partial Clinical Hold of Gemcabene (PR Newswire) -5.31%
May-20-20 04:29PM	NeuroBo Pharmaceuticals Reports First Quarter 2020 Financial Results (PR Newswire)
Apr-21-20 08:30AM	NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders (PR Newswire)
Apr-16-20 04:22PM	NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering (PR Newswire) -17.06%
Apr-14-20 09:15AM	NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering (PR Newswire) -43.27%
Mar-31-20 11:04AM	NeuroBo Pharmaceuticals (NASDAQ:NRBO) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +7.50%
Mar-30-20 04:30PM	NeuroBo Pharmaceuticals Reports Year End 2019 Financial Results and Provides Corporate Strategic Update (PR Newswire) -11.26%
Jan-13-20 09:00AM	NeuroBo Pharmaceuticals to Present at Biotech Showcase 2020 in San Francisco (Business Wire) -9.40%
Jan-10-20 05:00PM	NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger (Business Wire)

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRBO

NeuroBo Pharmaceuticals Inc

Upgrade your FINVIZ experience